Electra Therapeutics Reports $402.5 Million in Cash
The South San Francisco biotech posted a third-quarter 2026 net loss of $23.9 million after completing its September IPO.
Updated on Nov. 12, 2026 in Biotech

Electra Therapeutics reported third-quarter 2026 financial results, with cash, cash equivalents, and marketable securities totaling $402.5 million as of September 30, 2026. The company completed a $350 million IPO in September 2026, with net proceeds of $320.0 million.
Why it matters
The company reported a net loss of $23.9 million for the quarter as it advances its clinical programs. Electra expects its current cash position to support planned operations into 2029.
Electra reported $17.3 million in third-quarter research and development expenses and $7.8 million in general and administrative expenses. Net loss for the quarter totaled $23.9 million, and the filing does not break out spending by program.
The players
Electra Therapeutics
Electra Therapeutics is a clinical-stage biotechnology company headquartered in South San Francisco, California, developing antibody therapies that target signal regulatory protein pathways in immune cells.
The details
Electra's programs target signal regulatory proteins (SIRP), receptors whose expression rises upon immune cell activation. Ipsoprubart, a pan-SIRP monoclonal antibody, is in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH) and is being evaluated in relapsed or refractory T/NK cell malignancies, while ELA822 is in Phase 1 development. Two abstracts were accepted for poster presentations at the 2026 American Society of Hematology Annual Meeting.
Timeline
September 30, 2026: Third quarter ended and cash position was reported.
September 2026: Electra completed its IPO.
December 13, 2026: ASH abstract poster presentations are scheduled.
First half of 2027: ELA822 healthy volunteer data is expected.
Second half of 2027: Initial ipsoprubart data in T/NK cell malignancies and sHLH enrollment completion are expected.
Roadmap
Electra's ipsoprubart, a pan-SIRP antibody that selectively depletes pathogenic SIRPα/β1-positive myeloid cells and SIRPγ-positive T cells, has moved into a global registrational program for sHLH. The company's ELA822 candidate remains in Phase 1, placing its SIRP approach at different stages of clinical development.
For patients with sHLH or relapsed or refractory T/NK cell malignancies, the ipsoprubart program represents a potential future treatment option, though no timeline for approval is provided. The company's stated cash runway into 2029 indicates the programs are funded through the period of the planned data readouts.
The takeaway
Electra's funding and cash runway give its SIRP-targeting programs room to reach the upcoming 2027 data readouts. Readers tracking the biotech sector can watch those milestones as the clearest signals of whether the approach advances.
What happens next
ELA822 healthy volunteer data is expected in the first half of 2027, and initial ipsoprubart data in T/NK cell malignancies and sHLH enrollment completion are expected in the second half of 2027.
Further reading
Explore more Biotech coverage to see how other drug developers are advancing their pipelines.










